{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000107","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.257118+00:00","generated_at":"2026-05-17T04:36:11.666567+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus reports ARC-20 Phase 1/1b data: pooled ORR 31%, median PFS 12.2 mo; unveils 5 I&I preclinical programs","bullets":["ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).","50 mg QD cohort showed 36% ORR (incl. pending) and median PFS 19.2 mo; 100 mg QD showed 42% ORR (incl. pending).","Safety: Grade≥3 anemia 41%, hypoxia 11%; discontinuation rate 3%; no unexpected signals as of Aug 15, 2025 DCO.","Five new preclinical programs disclosed: MRGPRX2, TNFR1, CCR6, CD89, CD40L; first clinical study targeted in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000107","json":"https://secwatch.observer/filing/0001724521-25-000107.json","markdown":"https://secwatch.observer/filing/0001724521-25-000107.md","text":"https://secwatch.observer/filing/0001724521-25-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000107/0001724521-25-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000107/rcus-20251006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:36:11.666567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}